Pages that link to "Item:Q3078908"
From MaRDI portal
The following pages link to Monitoring the Rates of Composite Events with Censored Data in Phase II Clinical Trials (Q3078908):
Displaying 10 items.
- A Bayesian adaptive design for two-stage clinical trials with survival data (Q745979) (← links)
- Monitoring phase II comparative clinical trials with two endpoints and penalty for adverse events (Q1657815) (← links)
- Time-to-event continual reassessment method incorporating treatment cycle information with application to an oncology phase I trial (Q2931051) (← links)
- Joint monitoring and prediction of accrual and event times in clinical trials (Q3145573) (← links)
- Adaptive Randomization for Multiarm Comparative Clinical Trials Based on Joint Efficacy/Toxicity Outcomes (Q3183237) (← links)
- Quantitative assessment of adverse events in clinical trials: Comparison of methods at an interim and the final analysis (Q3299060) (← links)
- Risk-Group-Specific Dose Finding Based on an Average Toxicity Score (Q3576932) (← links)
- Ethical issues in oncology biostatistics (Q5424159) (← links)
- A covariate-adjusted adaptive design for two-stage clinical trials with survival data (Q6573267) (← links)
- A Bayesian hierarchical monitoring design for phase cancer clinical trials: incorporating information on response duration into monitoring rules (Q6627959) (← links)
